Targeting newly identified ERβ/TGF‐β1/SMAD3 signals with the FDA‐approved anti‐estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma

Wenbin Song(University of Rochester Medical Center), Shuyuan Yeh(University of Rochester)
Molecular Oncology
September 1, 2018
Cited by 31


Related Papers